Two clocks. One drug. And a lot of investors who only watch one.
If you’ve ever modeled a launch or a generic entry date based on “patent expiry,” you’ve probably been burned by the second clock you didn’t account for.
In pharma, timing isn’t just a le…

Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/

Small Molecules vs. Biologics: The “Same” Patent Fight—But Different Rules for Generics vs. Biosimilars
Most patent strategy conversations start with the same assumption: if you understand the reference product’s IP landscape, you can map the path to m…

Biopharma’s next revenue window isn’t in the lab—it’s in the tender.
For years, the industry has treated tender strategy as an afterthought: something to “figure out” once a molecule is nearing patent expiry. But in Europe, where procurement cycles, …

Pharma’s biggest “new drug” isn’t a new molecule—it’s a new story.
For years, investors and patients have been trained to look for the next breakthrough compound: novel targets, fresh mechanisms, first-in-class headlines. But a quieter engine has been …

Biopharma is entering a new kind of “cliff”—not just the patent cliff everyone talks about, but the operational cliff that shows up when exclusivity ends and pricing pressure hits overnight.
When a brand’s protection expires, the market doesn’t wait fo…

One-shot: How to pick the right drug patent for maximum term-extension value
Most pharma IP teams don’t lose on strategy—they lose on timing.
In a world where patent term extension (PTE) can be the difference between a blockbuster’s “tail” and a cliff,…

Drug patent litigation isn’t just about molecules—it’s about the design around.
In the last few years, we’ve seen a shift in how companies approach patent risk in pharmaceuticals. The headline is often the active ingredient. But the real battleground…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion question it can’t afford to get wrong: is it “patent term restoration” or “patent term adjustment”?
On paper, both sound like technical fixes to the same problem—time lost between patent filing and market entry. In practice,…